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Elimination is possible and is the only way to prevent the biggest loss of life and economic 
harm in the long run, says Andrew Lee. But Simon Thornley, Arthur J Morris, and Gerhard 
Sundborn argue that the cost to quality of life years is too big a risk when possible is not 
the same as achievable 
YesAndrew Lee 
Independent SAGE, a group of scientists providing independent scientific advice on 
covid-19, has called on the UK government to work towards a zero covid UK[1]in other 
words, the elimination of covid-19. 
Elimination is usually pursued for diseases that cause serious illness or death such as 
smallpox, polio, measles, and Ebola. The alternative approach is suppression, which attempts 
to reduce disease incidence to acceptable levels. This normally applies to low consequence 
infections, such as diarrhoeal diseases[2]the risk of death is low, and the disease continues 
to circulate in the population at low levels. 
It could be argued that pursuing elimination with intensive control measures, including 
societal lockdowns, is too costly. Indeed, in some major economies, gross domestic product 
(GDP) could fall by 20-25% because of control measures implemented so far in the 
pandemic.[3] Against the backdrop of rising unemployment and economic recession, 
suppression may seem the most economical approach. However, this is a short term 
perspective. Societal costs in the longer term need to be considered. 
Failure to eliminate 
Take influenza, for example. The 1918 flu pandemic is estimated to have killed 40 
million people worldwide and caused a 6% decline in GDP, similar in magnitude to the 2008-
09 recession.[4] Each year a billion people are infected with flu, and as many as 650ϛ000 die 
from it.[5] The costs of immunising, treating, and controlling flu are substantial. 
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The US alone spends over $8bn (£6.03bn; 6.77bn) a year in medical costs directly 
related to flu.[6] Lost productivity and national economic growth cost tens of billions more. 
Extrapolate this worldwide over decades, and the total costs are staggering. Seasonal flu 
epidemics also contribute to thousands of excess deaths each year. Failure to achieve 
elimination is a lose-lose solution, for both health and economic outcomes. 
Furthermore, covid-19 is not a low consequence infection. It is more contagious than flu 
and has high fatality rates, especially among elderly people and those with comorbidities.[7] 
Treatment can be costly, especially if intensive care is needed, and survivors may have long 
term health consequences.[8] A suppression approach means tolerating thousands of excess 
deaths each year, especially in vulnerable populations. 
Is elimination possible? Zero covid status has been achieved in New Zealand,[9] 
Vietnam, Brunei, and island states in the Caribbean.[10] We know what works: consistent 
adherence to physical distancing, hygiene practices, and ubiquitous use of face coverings, as 
well as the early detection, testing, tracing, and isolation of casesplus timely, targeted 
lockdowns to deal with local outbreaks. If and when a vaccine becomes available, mass 
immunisation programmes could help to boost population immunity. All of these measures 
taken together can work,[11] but they come at a cost. 
With large epidemics occurring worldwide, some people may consider elimination futile. 
In a globalised world, infections travel across continents within days. Travel restrictions and 
border control measures may stem the spread of infections.[12] Once the local disease 
incidence is low, health protection resources can be targeted at tackling imported cases. 
Indeed, over the years, health protection teams nationally have kept imported diseases such as 
typhoid fever, Ebola, and MERS-CoV at bay. Ultimately, global eradication is desirable
eliminating covid-19 everywhere, permanently. But this is challenging, and it will require 
global leadership and coordination.[13] 
Driving infections down 
Even if elimination is not achieved, the measures taken will drive infection numbers 
down to levels that make it more easily contained. The risk of community spread then 
becomes low, and normality can be restored for schools, businesses, and social life. 
Moreover, elimination measures are similar to suppression measures except that they are 
applied with greater force and rigour. These measures may also have the co-benefit of 
reducing other infections.[14] 
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This pandemic could still get worse. We do not know yet whether its spread will be 
enhanced by other winter infections[15] or whether mutations are increasing its 
infectiousness.[16] Unless elimination is achieved, covid-19 will become endemic[17]: 
recurrent outbreaks and seasonal epidemics will become the norm, with a grim toll in the 
human lives and wealth lost. 
NoSimon Thornley, Arthur J Morris, Gerhard Sundborn 
We would all like to eradicate covid-19 from the globe. However, closer scrutiny shows 
that the odds are heavily stacked against this as a sustainable, cost effective, long term 
strategy. New Zealands apparent three month success has recently been broken by a cluster 
with no known link to overseas travel. Ongoing lockdowns have now occurred in Auckland, 
and the country is still focusing on elimination. 
To consider the case of covid-19, and the notion of elimination itself, poses several 
questions. By prioritising elimination, do we believe that it is an important health issue, many 
times more deadly than other respiratory viruses? What is elimination, and how will we know 
that its been achieved? Where does elimination lead? What are the long term consequences 
of pursuing it, and what are the costs versus the benefits? 
First, how deadly is covid-19? Initially, the estimated infection fatality ratio was high 
when polymerase chain reaction tests were used to detect cases, and the denominator of this 
calculation was low. With the development of antibody assays its now clear that infection 
spread is much wider, and fatality ratio estimates now range from 0.02% to 0.86%, with a 
median of 0.26%,[18] similar to that for seasonal flu.[19] 
The ratio of deaths to the number of infections is also strongly age correlated: the age 
distribution of covid-19 deaths in New Zealand is similar to that from the same period in 
2019[20] (Fisher test P=0.93). This indicates that SARS-CoV-2 is not dramatically 
shortening life when compared with background survival. 
What is elimination? 
For measles, the World Health Organization defines regional elimination as no 
community transmission for more than 36 months, in the presence of good surveillance.[21] 
Genotyping evidence is also recommended to assess the interruption of endemic spread. After 
elimination is thought to have been achieved, the molecular information from new cases 
should be compared to ensure that these are different genotypes. To date, the only globally 
eradicated human disease is smallpox, which took 30 years to achieve. 
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Such a definition sets a very high bar, borne out by previous programmes. It also means 
that what New Zealand had achieved with no locally acquired cases in three months, although 
impressive, is far from the generally accepted definition of elimination. Pursuing this goal 
means permanently restricted borders, with relaxation contingent on an effective vaccine 
coming in less than 3-4 years as a best case scenario. 
How realistic are such time frames? Byram Bridle, a Canadian immunologist charged 
with developing such a vaccine, has said that the fastest historical development of a vaccine 
was four years (Merck: mumps),[22] while most take 10 years. However, vaccines for many 
viruses, such as HIV, may never arrive. And immuno-senescence in elderly people may blunt 
vaccine efficacy in this high risk age group.[23] 
A heavy cost 
With the virus now widespread globally and vaccines a distant possibility, a more 
sustainable strategy is for nations to learn to live with it. Heavily restricting borders 
indefinitely will severely damage economies and translate to unemployment, with strong 
relations to other illnesses and suicide.[24] 
Seeking elimination comes with a heavy cost. The New Zealand governments estimates, 
translated to quality adjusted life years, indicate that the costs outweighed the benefits of 
extended lockdowns designed to eliminate the virus, by a factor of 96:1.[25] A similar 
comparison in the UK estimated the costs of lockdown outweighing the benefits by 10:1.[26] 
Instead, we must protect our elderly people and should closely monitorand increase if 
neededthe capacity of our hospitals and public health services. Chasing an unrealistic goal 
comes with an unacceptably high price to our country that will take decades to repay. 
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